Aryl azoles based scaffolds for disrupting tumor microenvironment

Bioorg Med Chem. 2023 Nov 15:95:117490. doi: 10.1016/j.bmc.2023.117490. Epub 2023 Oct 14.

Abstract

Thirty-nine aryl azoles, thirteen triazoles and twenty-seven tetrazoles, have been synthetized and biologically evaluated to determine their activity as tumor microenvironment disruptors. Antiproliferative studies have been performed on tumor cell lines HT-29, A-549 and MCF-7 and on non-tumor cell line HEK-293. It has been studied in HT-29 the expression levels of biological targets which are involved in tumor microenvironment processes, such as PD-L1, CD-47, c-Myc and VEGFR-2. In addition, antiproliferative activity was evaluated when HT-29 were co-cultured with THP-1 monocytes and the secretion levels of IL-6 were also determined in these co-cultures. The angiogenesis effect of some selected compounds on HMEC-1 was also evaluated as well as their action against vasculogenic mimicry on HEK-293. Compounds bearing an amino group in the phenyl ring and a halogen atom in the benzyl ring showed promising results as tumor microenvironment disrupting agents. The most outstanding compound decrease dramatically the population of HT-29 cells when co-cultured with THP-1 monocytes and the levels of IL-6 secreted, as well as it showed moderate effects over PD-L1, CD-47 and c-Myc.

Keywords: Angiogenesis; Antiproliferative activity; CD-47; IL-6; PD-L1; Tetrazole; Triazole; Tumor microenvironment; VEGFR-2; c-Myc.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Azoles*
  • B7-H1 Antigen*
  • Cell Line, Tumor
  • HEK293 Cells
  • Humans
  • Interleukin-6
  • Tumor Microenvironment

Substances

  • Azoles
  • B7-H1 Antigen
  • Interleukin-6